Holders — by stockHoldings — by fund
Avidity Partners Management LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0001791827
$488.2M
disclosed book value
17
positions
34.3%
largest position share
Positions, as of 2026-09-30
top 18 of 17 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | DNTHDIANTHUS THERAPEUTICS INC | 1.9M | $167.3M | 34.3% |
| 2 | CGONCG ONCOLOGY INC | 1.3M | $95.6M | 19.6% |
| 3 | ORKAORUKA THERAPEUTICS INC | 785,424 | $65.4M | 13.4% |
| 4 | CGONCG ONCOLOGY INCCALL | 850,000 | $60.3M | 12.3% |
| 5 | JBIOJADE BIOSCIENCES INC | 2.0M | $28.1M | 5.8% |
| 6 | ELVNENLIVEN THERAPEUTICS INC | 550,000 | $25.2M | 5.2% |
| 7 | CATXPERSPECTIVE THERAPEUTICS INC | 6.1M | $16.7M | 3.4% |
| 8 | AKTSAKTIS ONCOLOGY INC | 484,200 | $9.4M | 1.9% |
| 9 | IMUXIMMUNIC INC | 669,941 | $6.2M | 1.3% |
| 10 | MOBIMOBIA MED INC | 324,676 | $3.1M | 0.6% |
| 11 | PVLAPALVELLA THERAPEUTICS INC NE | 20,000 | $2.8M | 0.6% |
| 12 | NVCTNUVECTIS PHARMA INC | 100,415 | $2.1M | 0.4% |
| 13 | MSLESATELLOS BIOSCIENCE INC | 164,019 | $1.4M | 0.3% |
| 14 | CNTXCONTEXT THERAPEUTICS INC | 4.1M | $1.2M | 0.2% |
| 15 | KPTIKARYOPHARM THERAPEUTICS INC | 884,900 | $1.1M | 0.2% |
| 16 | SENSSENSEONICS HLDGS INC | 100,000 | $1.0M | 0.2% |
| 17 | SCYXSCYNEXIS INC | 153,613 | $758,848 | 0.2% |
| 18 | AVLNAVALYN PHARMACEUTICALS INC | 20,000 | $569,800 | 0.1% |
Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.